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Abstract Pyomelanin is a brown/black extracellular
pigment with antioxidant and iron acquisition properties
that is produced by a number of different bacteria. Pro-
duction of pyomelanin in Pseudomonas aeruginosa con-
tributes to increased resistance to oxidative stress and
persistence in chronic infections. We demonstrate that
pyomelanin production can be inhibited by 2-[2-nitro-4-
(trifluoromethyl) benzoyl]-1,3-cyclohexanedione (NTBC).
This treatment increases sensitivity of pyomelanogenic P.
aeruginosa strains to oxidative stress, without altering the
growth rate or resistance to aminoglycosides. As such,
NTBC has potential to function as an anti-virulence factor
in treating pyomelanogenic bacterial infections.
Introduction
Pseudomonas aeruginosa is an environmental bacterium
that is capable of causing both acute and chronic infections
in compromised patients. This organism is extremely
adaptable, has a high level of intrinsic antibiotic resistance,
a wide range of virulence factors, and the ability to form
biofilms (reviewed in [1] ). Antibiotics are an essential part
of treating P. aeruginosa infections, but the inherent
resistance combined with emerging resistance due to
selective pressure limits the therapeutic options available.
As a new strategy to combat infectious disease, the specific
inhibition of virulence factors has been proposed as an
alternate treatment mechanism [2]. By attenuating bacterial
virulence without targeting essential bacterial pathways, it
may be possible to aid in the clearing of infections while
minimizing selective pressures that perpetuate resistance.
Pyomelanin, a dark brown/black pigment, is a potential
target for anti-virulence compounds. Pyomelanin production
has been reported in P. aeruginosa isolates from urinary tract
infections and chronically infected Cystic Fibrosis (CF)
patients [3, 4]. Pyomelanin is one of the many forms of mel-
anin that is produced by a wide variety of organisms. Pro-
duction of pyomelanin is reported to provide a survival
advantage, scavenge free radicals, bind various drugs, give
resistance to light and reactive oxygen species, and is involved
in iron reduction and acquisition, and extracellular electron
transfer [4–9]. A number of environmental and pathogenic
bacteria have been reported to produce this pigment [3, 8, 10–
14]. In Shewanella oneidensis and S. algae, pyomelanin plays
a role in biogeochemical cycling of metals, as pigment pro-
duction enhances hydrous ferric oxide reduction and electron
transfer [15–17]. In Legionella pneumophila, pigment pro-
duction may contribute to pathogenesis as pyomelanin
mediates ferric reduction from ferritin and transferrin [8].
Non-pyomelanogenic strains of Burkholderia cepacia are
more sensitive to externally generated oxidative stress and
show reduced survival in phagocytic cells [11]. In P. aeru-
ginosa, pyomelanin production results in increased persis-
tence and virulence in mouse infection models [3].
Pyomelanin is a negatively charged extracellular pig-
ment of high molecular weight, derived from the tyrosine
catabolism pathway [6, 18, 19]. 4-Hydroxyphenylpyruvate
is converted to homogentisate (HGA) by 4-hydroxyphen-
ylpyruvate dioxygenase (Hpd) (Fig. 1). HGA is then
converted to 4-maleylacetoacetate by homogentisate
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1,2-dioxygenase (HmgA). A loss of HmgA activity leads to
the accumulation of HGA, which is secreted via the ABC
transporter HatABCDE. Defects in either the ATP-binding
cassette or the permease components of this transporter
result in reduced pyomelanin production [4]. Once secreted
from the cell, HGA auto-oxidizes and self-polymerizes to
form pyomelanin. Both point mutations in hmgA and
chromosomal deletions have been reported in clinical
P. aeruginosa isolates producing pyomelanin [3, 10].
Hpd activity is essential for the synthesis of HGA, and
ostensibly irreversible binding with 2-[2-nitro-4-(trifluoro-
methyl)benzoyl]-1,3-cyclohexanedione (NTBC) inhibits Hpd
activity of Streptomyces avermitilis in vitro [20]. Although it was
originally developed as an herbicide, NTBC is a FDA-approved
treatment for type I tyrosinemia [21]. Type I tyrosinemia is the
result of a defect in the tyrosine catabolism pathway, which
causes the accumulation of toxic metabolites such as fumaryl-
acetoacetate, leading to cirrhosis and cancer of the liver [22].
Binding of NTBC to Hpd prevents the accumulation of toxic
metabolites and disease progression [21]. We report here on
NTBCtreatmentofpyomelanogenic strainsofP.aeruginosa, the
resulting reduction in pyomelanin production, and the corre-
sponding increase in sensitivity to oxidative stress.
Materials and Methods
Bacterial Strains and Growth Conditions
Laboratory strains of P. aeruginosa PAO1 (obtained from
Carrie Harwood, University of Washington), transposon
mutants hpd::tn (PW2577) and hmgA::tn (PW4489)) and
the clinical isolate PA1111 were grown at 37 C in LB
supplemented with tetracycline (60 lg/ml) and gentamycin
(50 lg/ml) as appropriate. The transposon mutants were
obtained from the University of Washington transposon
mutant collection [23]. Escherichia coli DH5a (NEB) was
used as a host for recombinant plasmids, and was grown in
LB with gentamycin (10 lg/ml) as appropriate.
Chemicals
NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohex-
anedione), H2O2, and tobramycin were purchased from
Sigma-Aldrich. Gentamycin and kanamycin were pur-
chased from Gold Bio and Fisher Scientific, respectively.
Growth Curves
Overnight cultures were grown in LB ? 300 lM NTBC or
LB with the corresponding amount of DMSO. The over-
night cultures were diluted to OD600 0.05 in LB ? 300 lM
NTBC or LB ? DMSO, and the optical density was
measured every hour. Each sample was pelleted and
resuspended in LB prior to the optical density reading to
ensure that the results were not influenced by the presence
of pyomelanin.
Oxidative Stress Assay
Overnight cultures were grown with NTBC (300 lM) or
with a corresponding volume of DMSO as a control.
Optical densities (OD600) were measured using washed
cells, and cultures were diluted to equivalent OD600 values
(*2.5). Tenfold serial dilutions were made in PBS con-
taining either 300 lM NTBC or DMSO as appropriate.
5 lL of each serial dilution was spotted onto LB plates
containing the indicated concentration of H2O2. Laboratory
strains were incubated for 24 h and PA1111 was incubated
for 45 h at 37 C.
Determination of MICs
Minimal inhibitory concentrations (MICs) were deter-
mined by twofold serial microtiter broth dilution [24],
using an inoculum of 2.75 9 105 CFU/ml. Inoculum con-
centration was determined using washed cells to ensure
that pyomelanin production did not affect OD600 readings.
NTBC was included in the appropriate wells at a final
concentration of 300 lM. MICs were recorded as the
lowest concentration of antibiotic inhibiting growth fol-
lowing 24 h of incubation at 37 C.
Fig. 1 Tyrosine catabolism pathway of Pseudomonas aeruginosa.
Inactivation of HmgA results in the secretion of HGA, which auto-
oxidizes and self-polymerizes to form pyomelanin. NTBC inhibits
HGA production and pyomelanin formation through interactions with
Hpd
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Results and Discussion
Pyomelanin Production by a Clinical Isolate
of P. aeruginosa
PA1111, a pyomelanogenic clinical isolate from an acute
infection, was obtained from Dara Frank (Medical College
of Wisconsin). This strain lacked type III secretion proteins
but was cytotoxic in a tissue culture assay [25]. To deter-
mine the cause of pyomelanin production in this isolate,
HmgA (PA2009) from PAO1 was expressed from pJN105
[26]. Following induction with 0.05 % and 0.1 % arabi-
nose, pyomelanin production was eliminated in hmgA::tn
and PA1111, respectively (Online resource 1a). P. aeru-
ginosa hmgA::tn functions as a positive control for pyo-
melanin production as hmgA is interrupted with the
ISphoA/hah transposon [23]. P. aeruginosa PAO1 and
hpd::tn (isogenic to hmgA::tn) were included as negative
controls; neither strain produces pyomelanin.
Since increased amounts of arabinose were required to
eliminate pyomelanin production in PA1111 relative to
hmgA::tn (compare 0.05–0.1 %), we assayed hpd transcript
levels through RT-PCR (Online resource 1b). Quantifica-
tion of the relative levels revealed that in both PAO1 and
PA1111 hpd transcript was approximately 10 % more
abundant than in hmgA::tn. It is unlikely that this subtle
increase in hpd transcript levels is responsible for the
residual pyomelanin production in PA1111 at low levels of
induction (0.05 % arabinose). This suggests that the clini-
cal isolate may have altered translation or post-translational
modification resulting in increased expression or activity of
Hpd.
The ability to abolish pyomelanin production in PA1111
through expression of wild-type HmgA suggested that
either a chromosomal deletion or inactivation of the hmgA
gene occurred, both of which have been reported in clinical
isolates of P. aeruginosa [3, 10]. A third reported cause of
pyomelanin production is imbalanced enzyme expression
within the L-tyrosine catabolism pathway. In Vibrio chol-
erae (ATCC 14035), homogentisate dioxygenase and the
downstream enzymes are expressed at lower levels than
hydroxyphenylpyruvate dioxygenase, leading to an accu-
mulation of HGA and pyomelanin production [27]. To
determine the genetic cause of pyomelanin production in
PA1111, we attempted to PCR amplify and sequence
hmgA. Despite repeated attempts, we were unable to
amplify hmgA via colony PCR. To verify these results,
Southern hybridization was performed with DIG-labeled
hmgA as a probe. No hybridization was detected between
the hmgA probe and the PA1111 genome (data not shown).
This, combined with our ability to complement the pyo-
melanin phenotype via induction of hmgA expression,
suggests that a chromosomal deletion has occurred.
NTBC Inhibits Pyomelanin Production in Pseudomonas
aeruginosa Without Disrupting Growth
NTBC is known to bind Hpd (4-hydroxyphenylpyruvate
dioxygenase) and inhibit the conversion of 4-hydroxy-
phenylpyruvate to homogentisate [20]. We, therefore,
assayed NTBC treatment for disruption of pyomelanin
production in P. aeruginosa. The two pyomelanin-pro-
ducing strains (hmgA::tn and PA1111) were grown over-
night with increasing amounts of NTBC. Following
overnight growth, inhibition of pyomelanin production was
determined visually (Fig. 2a). NTBC (300 lM) inhibited
pyomelanin production in hmgA::tn, while PA1111
required higher concentrations of NTBC to inhibit
Fig. 2 NTBC treatment inhibits pyomelanin production without
affecting growth. a Pyomelanin production by P. aeruginosa with
and without NTBC treatment. Laboratory and clinical strains were
grown overnight with the indicated concentrations of NTBC.
b Growth curves of laboratory and clinical strains of P. aeruginosa
with and without 300 mM NTBC treatment. Strains grown without
NTBC are indicated with closed symbols, while those grown with
NTBC are indicated with open symbols. Wild-type PAO1 (dia-
monds), hpd::tn (triangles), hmgA::tn (squares), PA1111 (circles).
The growth curves are compiled from three independent experiments,
with error bars indicating standard error of the mean
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pyomelanin production (900 lM). Sequencing of
hpdPA1111 revealed two silent mutations upon comparison
with hpdPAO1 (PA0865), demonstrating that mutations
within Hpd were not responsible for the residual PA1111
pyomelanin production in the presence of 300 lM NTBC.
To ensure that NTBC did not alter the growth of P. aeru-
ginosa, we measured the optical densities of cultures grown
in the presence and absence of NTBC. The laboratory
strains and PA1111 grew at the same rate in the presence or
absence of 300 lM NTBC (Fig. 2b), indicating that the
reduction in pigmentation was not due to altered growth
rates.
NTBC Treatment of Pyomelanogenic Strains does
not Alter Aminoglycoside MICs
It has been reported that melanin has the ability to non-
specifically bind a number of diverse compounds. Isotherm
analysis indicated that gentamycin had a high level of
binding to synthetic melanin through a series of diverse
interactions [28]. Melanin–tobramycin interactions have
resulted in a decrease of antibiotic activity of 80 % under
certain conditions [29]. Aminoglycosides are positively
charged at physiological pH, which may contribute to the
interactions with negatively charged melanin [6]. Further-
more, a significant correlation was seen between
pyomelanin production in Stenotrophomonas maltophilia
and resistance to specific antibiotics [14]. We therefore
assayed both pyomelanin producing and non-producing
strains (with and without NTBC treatment) to determine
the minimal inhibitory concentrations (MICs) of
aminoglycosides.
Minimal inhibitory concentrations were determined by
twofold serial microtiter broth dilution [24]. Our results
indicated that, under these conditions, the pyomela-
nin producing strains (hmgA::tn and PA1111) did not show
significantly higher aminoglycoside MICs than the non-
pyomelanin producing strains (PAO1 and hpd::tn,
Table 1). While treatment of the pyomelanin producing
strains with NTBC did inhibit pyomelanin production, the
MICs remained unchanged. These data indicated that nei-
ther pyomelanin production nor NTBC treatment affect the
aminoglycoside MICs for P. aeruginosa. This is in agree-
ment with an earlier study wherein MICs were unaltered by
pyomelanin production [3], and provides further clarity to
the discussion within the literature regarding pyomelanin
production and antibiotic resistance. Early studies of pyo-
melanin production reported that pyomelanogenic P.
aeruginosa isolates were more sensitive to antibiotics when
compared to non-pyomelanogenic strains [30]. In contrast,
when Staphylococcus aureus was incubated in supernatant
from pyomelanogenic P. aeruginosa, the MIC values
Table 1 Aminoglycoside MICs (lg/ml) of laboratory and clinical isolates of P. aeruginosa
PAO1 hmgA::tn hpd::tn PA1111
- NTBC ? NTBC -NTBC ?NTBC -NTBC ?NTBC -NTBC ?NTBC
Gentamycin 1 0.5 2 2 1 1 0.5 0.5
Kanamycin 16 8 32 32 32 32 16 16
Tobramycin 0.5 0.5 0.5 0.5 0.25 0.25 0.5 0.5
Three independent colonies were tested in triplicate for each strain
Fig. 3 NTBC treatment increases H2O2 sensitivity in pyomelanin producing strains. 10-fold serial dilutions of the indicated strains were spotted
onto LB plates containing the indicated concentrations of hydrogen peroxide
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remained unchanged [31]. When considering the results of
these studies, it is critical to consider the sources of the
melanin; the isotherm analysis was conducted with
eumelanin (or synthetic melanin) generated from 3,4-
dihydroxyphenylalanine (DOPA), not pyomelanin gener-
ated from homogentisate [6]. It is possible that the dis-
crepancy between our results and the isotherm studies is
due to the differences in melanin structures (G. Moran,
personal communication). While the S. maltophilia studies
did correlate pyomelanin production with increased resis-
tance to some b-lactam antibiotics and fluoroquinolones,
resistance was not detected to either gentamycin or tri-
methoprim/sulfamethoxazole [14]. Importantly, a direct
causal relationship was not tested, and the authors
acknowledged that these phenotypes could have resulted
from independent mutations.
NTBC Treatment of Pyomelanin-Producing
P. aeruginosa Increases Sensitivity to Oxidative Stress
The antioxidant properties of pyomelanin are proposed to
contribute to the increased persistence and virulence of
pyomelanogenic bacteria in infection models [3, 11, 12].
Since pyomelanogenic strains of Burkholderia cepacia and
P. aeruginosa have increased resistance to hydrogen per-
oxide, we examined if NTBC treatment increased sensi-
tivity of pyomelanogenic strains of P. aeruginosa to
oxidative stress.
The H2O2 spot plates showed that both pyomelanogenic
strains (hmgA::tn and PA1111) have increased resistance to
hydrogen peroxide relative to the non-pyomelanogenic
strains (PAO1 and hpd::tn) (Fig. 3). Importantly, NTBC
treatment of pyomelanogenic strains resulted in increased
sensitivity to 0.6 mM H2O2. This illustrates the potential
use of NTBC as an anti-virulence factor. The change in
sensitivity to H2O2 was smaller for PA1111 than hmgA::tn,
and resulted in an approximately 24 % reduction in number
of PA1111 colony forming units (based on 4 independent
experiments). It is likely that the residual pyomelanin
produced in PA1111 at 300 lM NTBC provides a small
level of protection against oxidative stress compared to
hmgA::tn. As expected, NTBC treatment of either wild-
type PAO1 or hpd::tn did not affect sensitivity to H2O2.
In this report, we determined that the pyomelanin pro-
duction in a strain of P. aeruginosa PA1111 isolated from
an acute infection was likely due to the loss of HmgA
activity resulting from a chromosomal deletion [25]. This
phenotype has previously been reported for CF isolates and
has been shown to decrease clearance/increase persistence
in mouse models of chronic infection, suggesting that the
development of pyomelanin production may confer an
adaptive advantage [3, 10]. Given the antioxidant proper-
ties of pyomelanin, it is likely that pigment production
would provide protection from oxidative stress in both
chronic and acute infections.
This study has shown that NTBC treatment inhibited
pyomelanin production by P. aeruginosa, and in doing so
increased the sensitivity of both laboratory and clinical
isolates to oxidative stress, as is found in the respiratory
burst from macrophages and monocytes. This suggests that
NTBC, as an already FDA-approved compound, has
potential as an anti-virulence factor that could be used in
combination with existing antibiotics. Pyomelanin is made
by a wide variety of organisms, and has been reported in
both chronic and acute infections. Given the number of
organisms that produce pyomelanin, its functions in iron
acquisition and as an antioxidant, and the presence of
pyomelanin in both acute and chronic infections, there are
a high number of potential applications of NTBC as an
anti-virulence factor.
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